Share This

Related Topics News -

     
 Title only   |   Print 
     
樂普生物治療晚期實體瘤藥物臨床試驗完成首例受試者首次給藥

2024-04-15T  
《公司業績》樂普生物-B去年虧損收窄至2,209.6萬元人民幣

2024-03-28T  
樂普生物-B治療胰腺癌候選藥物獲美國授予快速通道資格

2024-03-11T  
樂普生物-B(02157.HK)治療鼻咽癌藥物臨床完成全體受試者入組 股價曾升逾7%

2023-12-29T  
樂普生物(02157.HK)MRG004A用於治療胰腺癌適應症獲FDA孤兒藥認定

2023-12-14T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.